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apy mobilization and growth factor administration. Apheresis per-
formed on the week-end may increase resource utilization com-
pared to apheresis during the week. In order to decrease the
likelihood of week-end collections, we analyzed the timing of
apheresis with respect to chemotherapy administration and devel-
oped an optimized schedule for chemotherapy, growth factors, and
apheresis. Methods: A retrospective analysis of mobilization of
auto-grafts in 41 patients with lymphoid malignancies (NHL, MM,
HD) was performed. Chemotherapy mobilization regimes in-
cluded cyclophosphamide (n  14), CHOP, ICE, or VTEPA (n 
15), Hyper CVAD (n  8), or DT-PACE (n  4). G-CSF was
administered S.Q. once daily at a dose of 5 mcg/kg starting two
days after the last day of chemotherapy. GM-CSF was added at a
dose of 5 mcg/kg every evening starting on the 8th day after
chemotherapy. Apheresis began when the blood CD34 cells
were  20/uL. Results: The median number of CD34 cells
collected in all 66 patients was 8  10E6/kg (range 1 to 79 
10E6/kg) following a median of 2 days of apheresis. The median
number of days between the last day of chemotherapy and the ﬁrst
day of apheresis was not signiﬁcantly different between the entire
cohort of 66 patients (median 12 days, range 8-24 days) or the
subsets of patients who received cyclophosphamide (12 days),
CHOP, ICE, or VTEPA (11 days), Hyper CVAD (11 days) or
DTPACE (15 days). Among the initial 41 patients analyzed, 29%
of patients required apheresis during the week-end. Administration
of the last dose of chemotherapy on Thursday/Friday versus Tues-
day/Wednesday was associated with a reduced rate of week-end
apheresis collections (p  0.009). An optimized schedule of che-
motherapy ending on Friday was implemented in order to avoid
week-end collections and applied in 25 subsequent patients. Using
the new schema for chemo-mobilization the incidence of week-end
apheresis was reduced to 14% in the next group of 14 patients.
Among 11 patients not treated according to the new schema, the
incidence of week-end collections was 27%. Conclusion: The ﬁrst
day of apheresis can be generally predicted as occurring 11-15 days
after the last dose of chemotherapy using a combination of G-CSF
and GM-CSF treatment when these growth factors are sequentially
administered 2 and 8 days after the last dose of chemotherapy.
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IMPACT OF AGE ON OUTCOME OF AUTOLOGOUS STEM CELL TRANS-
PLANT FOR FOLLICULAR AND DIFFUSE LARGE B CELL LYMPHOMA
Arora, A., Vose, J.M., Lynch, J., Armitage, J.O., Bierman, P., Bociek,
G.R., Weisenburger, D.D. University of Nebraska Medical Center,
Omaha, NE
Incidence of Non-Hodgkins Lymphoma (NHL) rises with age.
The median age of diagnosis is 60 years. We report the impact of
age on the outcome of patients who received high dose chemo-
therapy and autologous hematopoietic stem cell transplant (HDC/
AHSCT) for follicular or diffuse large B cell lymphoma from April
1983 to June 2001. 50/484 (10%) were age 60 years with median
age of 65 years (range: 60-73). 434/484 (90%) were 60 years of
age with median age of 45 years (range 16-59). Patients 60 years
and above were more likely to have diffuse large B cell lymphoma
(84% Vs 51%, p 0.0001). Stage 3 or 4 disease was more common
in patients 60 years (32% Vs 48%, p  0.03). Other character-
istics which includes: median time from diagnosis to transplant,
number of prior chemotherapies, extranodal involvement, disease
status at transplant, LDH level and chemosensitivity did not show
any signiﬁcant differences between the two age groups. Approxi-
mately 30% of patients in each age group had received three or
more chemotherapies. Majority of the patients received BEAC/
BEAM as the conditioning regimen with peripheral hematopoietic
stem cells as the source of transplant. The median follow-up of
surviving patients was 5.9 years (range 1.5-19.2). Patients 60 years
and above had a signiﬁcantly poor 5-year event free survival rate
(27% Vs. 39%, p  0.01) and overall survival rate (31% Vs. 54%,
p  0.01) when compared to patients less than 60 years of age. On
multivariate analysis, age60 years (HR 4.4, 95% CI 1.7-11.6, p
0.01) and use of three or more chemotherapy regimens (HR 2.2,
95% CI 1.2-4.1, p  0.01) were independent risk factors for an
adverse event. Age 60 years (HR 6.5, CI 2.1-20.2, p  0.01),
female sex (HR 2.1, 95% CI 1.1-4.1, p  0.03), use of three or
more chemotherapy regimens (HR 2.9 95% CI 1.4-5.7, p  0.01),
disease resistant to chemotherapy (HR 3.5, 95% CI 1.3-9.6, p 
0.01) were independent risk factors for death. In conclusion, ad-
vanced age is a strong and independent risk factor for outcome.
AHSCT should be offered early in the course of relapse. Various
strategies that include immunotherpy and other novel treatment
are needed to improve chemoresistance in patients receiving
HDC/AHSCT.
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HIGH DOSE SEQUENTIAL (HDS) FOLLOWED BY AUTOLOGOUS BONE
MARROW TRANSPLANTATION (ABMT) AS SALVAGE TREATMENT IN
ADVANCED HODGKIN’S DISEASE (HD)
Delamain, M.T., Cardoso, R.B., Pagnano, K.B., Oliveira, G.B., Lo-
rand-Metze, I., Vigorito, A.C., Aranha, F.J.P., Eid, K.B., Miranda,
E.C.M., De Souza, C.A. Hematology and Blood Transfusion Center-
State University of Campinas-UNICAMP, Campinas, Sa˜o Paulo, Brazil
ABMT has been proposed as a salvage treatment of resistant/
refractory HD. HDS using Cy 7g/m2 for debulking and PBPC
mobilization followed by MTX 8g/m2 and then VP-16 2g/m2
before ABMT, described by Milan group, seems to be effective in
these patients. We report the results obtained using this procedure
in 31 patients with HD who failed conventional therapy or relapsed
within 24 months of conventional chemo /radiotherapy. Pa-
tients were treated with HDS followed by ABMT receiving BEAM
(BCNU, Etoposide, Ara-C and Melphalan) as conditioning regi-
men. The median age was 25 years (12-61), 20 male (64,5%) and
11 female (35,5%). The histology at diagnosis showed: 19 (61,3%)
nodular sclerosis; 9 (29%) mixed cellularity; 2 (6,5%) lymphocyte-
depleted and 1 (3,2%) lymphocyte-rich HD. Bulky disease was
presented in 15/31 (49%) patients and 6/31 (20%) had bone mar-
row inﬁltration. The Overall survival (OS) and disease free survival
(DFS) were 49% (n  31) and 60% (n  15), respectively, in 1825
days. The OS was 62% for patients with 0-1 prognostic factors at
diagnosis and a shorter OS was observed in patients with more than
2 prognostic factors (P  0.004). Bulky disease , histology type and
bone marrow involvement did not correlate with poor outcome.
Fifteen patients died, 8/15 due to progressive disease (53%), 5/15
due to toxicity after the HDS (33%) and 2/15 due to toxicity after
ABMT (13%). Status presens for alive patients after a median time
of 783 days (range 50-1929) from transplant is: CR 11 (35,5%),
partial response 2 (6,5%) and 4 in progressive disease (12,9%). We
conclude that HDS followed by ABMT is an effective salvage
regimen for patients with resistant/refractory Hodgkin’s disease
and probably induces a long and stable CR mainly in chemosen-
sitive patients. Patients presenting 2 prognostic factors at diag-
nosis presented worst outcome.
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AUTOLOGOUS STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA
AND LYMPHOMA WITHOUT TRANSFUSION SUPPORT
Ford, P.A.1, Matthews, B.A.2 1. Pennsylvania Hospital, Philadelphia,
PA; 2. Pennsylvania Oncology Hematology Associates, Philadelphia, PA
High-dose chemotherapy (HDCT) and autologous peripheral
blood stem cell transplantation (APBSCT) results in signiﬁcant
anemia and thrombocytopenia with transfusion support felt to be
necessary in all patients. Our center was the ﬁrst to perform stem
cell transplantation without the use of blood products in Jehovah
Witness’s who decline transfusions based on religious convictions.
Table. Relationship Between Timing of Chemotherapy and Percentage
of Patients Pheresed on Weekends
Last Day of
Chemo Sunday Monday Tuesday Wednesday Thursday Friday Saturday
% pheresed
Saturday
or Sunday 11% 33% 44% 50% 0% 16% 25%
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Our program has transplanted 28 patients to date. The ﬁrst step of
our bloodless transplant protocol employs the use of aggressive
doses of erythropoietin and intravenous iron to a target Hg of 11
g/dL. Apheresis causes anemia and thrombocytopenia necessitat-
ing an average 14 day delay before HDCT allowing the patient’s
hemoglobin and platelet levels to reach 11 g/dL and 100,000
cells/mm3. Standard doses of chemotherapy with BCV (BCNU,
Carboplatin, and VP16) or Melphalan (150-200mg/m2) were ad-
ministered. Routine blood conservation techniques were utilized.
Erythropoietin, intravenous iron, vitamin C, folate, and B complex
were given after transplant to facilitate red blood cell recovery. The
single mortality was attributed to pre-transplant hemoglobin of 7
g/dL at which time our protocol was amended to require a hemo-
globin level of 11g/dL before HDCT. To prevent bleeding, the
patients were prophylactically placed on Interleukin (IL)-11 with
Amicar and vitamin K added when the platelet count fell below
30,000 cells/mcL. Apheresis catheters were removed the day after
reinfusion before thrombocytopenia occurred. No signiﬁcant
bleeding occurred with platelet counts exceeding 5000 cells/mm3.
Hematologic data are outlined in table 1: Individuals unwilling to
accept blood products can undergo HDCT and APBSCT with an
acceptable rate of morbidity and mortality. Blood conservation
techniques may limit the number of transfusions thereby further
decreasing transplant related complications. Public safety concerns
related to transfusion risks, increasing blood shortages and eco-
nomics may require us to establish better transfusion guidelines.
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ONE-YEAR FOLLOWUP: PERIPHERAL CD34 COUNTS TO GUIDE LEU-
KAPHERESIS IN PERIPHERAL HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Grifﬁn, D.L., Donnenberg, A.D., Kiss, J.E., Agha, M.E. University of
Pittsburgh Cancer Institute, Pittsburgh, PA
We previously reported at this meeting a multiparameter model
to predict CD34 collection on the basis of peripheral CD34 counts
obtained on the day of leukapheresis, in conjunction with several
clinical indicators (autologous vs allogeneic, collection number,
gender, length of collection). The model can be expressed: LOG
CD34/kg CONSTANT LOG PB_ABS_CD34 3_HOUR
AUTO  MALE  COL_NO. Where PB_ABS_CD34 is the
absolute peripheral CD34 count in cells/microliter, 3_HOUR in-
dicates length of apheresis collection (0 if 4 hour, 1 if 3 hour),
AUTO indicates transplant type (0 if allo, 1 if auto), MALE
indicates gender (0 if female, 1 if male), and COL_NO indicates
collection number. This model was implemented in 3 phases, with
a learning set (n  60) to create the model, a testing set (n  203)
to validate the model on data not included in the learning set, and
a prospective implementation phase of a reﬁned model based on
the entire data set. The ﬁnal model had coefﬁcients of 5.169, 0.986,
0.151, 0.077, 0.058, and 0.028 (corresponding to the above
equation). This model was capable of predicting actual collections
with an intercept of 0.05, a slope of 1.006, and an R2 of 0.930.
During the prospective implementation phase we attempted to use
this model to determine whether a patient was eligible to initiate
collection. Patients scheduled for a possible ﬁrst collection re-
ported to the outpatient clinic in the morning and had blood drawn
for peripheral CD34 determinations (mean turnaround time  1
hour). The predicted CD34 collection (CD34/kg) was estimated
according to the model and reported to the patient coordinator.
Despite the rapid result reporting, implementation of this algo-
rithm disrupted the clinical schedule and proved infeasible. We
now report a modiﬁed model based on peripheral CD34 counts
obtained the day prior to the day of anticipated initiation of
leukapheresis. The additional parameters included in this model
were disease (multiple myeloma vs other), collection number and
transplant type. The learning data set (n 132) was able to predict
CD34 collection with an R2 of 0.811. Although this was not as
close a ﬁt as the previous model, analysis of sensitivity and speci-
ﬁcity (predicting whether a given collection would yield greater
than 5 105 CD34/kg) revealed a positive predictive value of 84%
and a negative predictive value of 75%. We are now determining
how best to implement this predictive tool in the clinical setting.
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DMSO REMOVAL REDUCES STEM-CELL INFUSION-RELATED TOXICITY
AND ALLOWS EXCELLENT ENGRAFTMENT OF CRYOPRESERVED UN-
RELATED CORD BLOOD AND AUTOLOGOUS STEM CELLS
Oliveira, O.M.W.1, Vieira, M.J.1, Bastos, E.M.S.C.1, Delbuono, E.1,
Ginani, V.C.1, Gordan, L.1, Gouveia, R.V.1, Cecyn, K.Z.2, Carvalho,
M.L.2, Lee, M.L.M.1, Petrilli, A.S.1, Seber, A.1 1. Pediatric Oncology
Institute-GRAACC-UNIFESP, Sao Paulo, SP, Brazil; 2. Hematology
and Hematotherapy-Federal University of Sao Paulo, Sao Paulo, SP,
Brazil
The reinfusion of cryopreserved stem cells (SC) can be associated
with allergies, vomiting, seizures and acute renal failure. All these
reactions may be attributed to the DMSO that is infused with the
stem cells. Since 1999, we have removed the DMSO for all pedi-
atric patients weighting 25 kg, with a DMSO dose 1 g/kg or
with underlying renal or cardiac compromise. Methods: DMSO
was removed according to the New York Blood Center guidelines
for thawing and washing cord blood (CB) units. Brieﬂy, a 1:1
Dextran40 5% albumin solution was slowly added to the SC
product immediately after thawing in a 37°C water bath. The cells
were at ﬁrst washed in 50cc tubes and now, only bags are used. The
bags are centrifuged 400g, 4°C for 20 minutes. The buffy coat is
re-suspended in the same solution and infused over 30 minutes.
The objective of this study is to compare cell yield, viability,
sterility, side effects associated to infusion and engraftment in
children undergoing BMT with unmanipulated grafts or after
DMSO removal. Results: Twenty-six patients with underlying
malignancies were evaluated; 20 received autologous PBSC, 11 of
them with DMSO removal. DMSO was removed from all 6 un-
related CB units. The patients in the groups with and without
DMSO removal had a median age of 5 and 4 years and weighted 18
and 17kg, respectively. In CB transplants the mean mononuclear
cell (MNC) dose was 3  107/kg (2-6). Viability was 80% (53-96).
Cell recovery after thawing was 93% (82-100) and after the DMSO
removal, 96% (73-100). All patients engrafted after a mean of 17
days (11-22). In patients undergoing autologous PBSC transplants
with and without DMSO removal, the mean MNC dose was 7
(2-10) and 9 (3-21) 108/kg, respectively. After thawing, the mean
cell viability was 78% (64-95) and 76% (46-89). Cell recovery was
88% (55-111) and 94% (90-97) and 81% (51-100) after the DMSO
removal. All patients engrafted after a mean of 10 (8-13) vs. 11
(8-15) days, respectively. The patients who receive DMSO-free
grafts did not have any serious adverse reactions associated to the
infusion. Patients for whom the DMSO was not removed had
seizures (1), hypervolemia (2), cardiac arrest (1) and all had some
degree of nausea, vomiting and chills. Conclusions: DMSO re-
moval is safe, reduces the infusion-related toxicity in pediatric
BMT without signiﬁcant cell loss or contamination. Engraftment
is satisfactory in both autologous PBSC and unrelated cord blood
transplants.
Table. Hematologic Data
All
Patients*
(n  28)
Multiple
Myeloma
(n  10)
Lymphoma
(n  16)
Average Hb@ onset
of HDCT (g/dL) 12 13 11.6
Average change in Hb
(g/dL) 5.3 4.7 5.9
Average # Days plts
< 10 (cells/mm3) 4.7 2.5 6.1
Average lowest plts
(cells/mm3) (Nadir
and Range) 5.0 (1-36) 9 (2-36) 5.8 (1-13)
*Includes 2 breast cancer patients.
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